Trade Secrets: Implications for Pharmaceutical Innovation and Access Thursday, 24 September 2020 | 4:00pm-5:00pm CET |
The implications of intellectual property rights for innovation and access to medicines is a highly debated topic. While most of the discussion focuses on patents and other kinds of exclusive rights, much less attention is paid to trade secrets (namely IPRs on confidential information that may be sold or licensed). Trade secrets can restrict access to critical information relevant to product R&D, manufacturing and commercialisation, acting as potential barriers hampering the development and widespread use of health technologies. Professor David Levine will explore how the current Covid-19 pandemic provides a unique opportunity to apply exceptions and limitations foreseen in international trade laws in the public interest to advance equitable access to life saving diagnostics, treatments, medicines, and vaccines that may hinge on robust information access. Speakers David Levine Associate Professor, Elon University School of Law; Affiliate Scholar, Center for Internet and Society, Stanford Law School Suerie Moon Co-Director, Global Health Centre REGISTER NOW Event Materials Paper: COVID-19 Trade Secrets and Information Access: an Overview, David Levine Paper: Why Do Startups Use Trade Secrets? David Levine and Ted Sichelman Biographies of Speakers This webinar is part of a GHC project, the Knowledge Network for Innovation and Access to Medicines. |